Toft Group Completes Executive Search for Vice President, Business Development for Inivata in Research Triangle Park, NC

Executive search firm Toft Group has placed Thomas Schlumpberger, PhD, as Vice President of Business Development for Inivata in Research Triangle Park, NC.

Dr. Schlumpberger was previously Head of Diagnostic Business and Vice President, Diagnostics with Singulex. Prior to that, he held leadership positions at Annai Systems and AliveCor. Dr. Schlumpberger served as the Chief Commercial Officer at Invitae (f/k/a Locus Development). Earlier in his industry career, Thomas served with Epocal as Senior Vice President of International Sales and Business Development. He currently sits on the board of DxEconomics and serves as Deal Advisor to CroMedX.

Dr. Schlumpberger holds a PhD in Molecular and Cell Biology from the University of California, Berkeley, and an MS in Electrical Engineering and Information Theory from the Technical University, Munich, Germany.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Inivata

Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care.  Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision® liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with select multi-gene panels to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies.  The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK.